Losartan and Immune Checkpoint Inhibitors in Glioblastoma: An Appropriate Substitute for Steroids

Overview

Journal Ann Neurosci

Publisher Sage Publications

Specialty Neurology

Date 2024 Aug 19

PMID 39156623

Authors

Burhanuddin Sohail Rangwala

Areej Shakil

Muhammad Saqlain Mustafa

Hussain Sohail Rangwala

Hareer Fatima

Mohammad Arham Siddiq

Affiliations

Soon will be listed here.

Citing Articles

Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.

Duraj T, Kalamian M, Zuccoli G, Maroon J, DAgostino D, Scheck A BMC Med. 2024; 22(1):578.

PMID: 39639257 PMC: 11622503. DOI: 10.1186/s12916-024-03775-4.

Accuracy of MRI in Detecting 1p/19q Co-deletion Status of Gliomas: A Single-Center Retrospective Study.

Naeem A, Aziz N, Nasir M, Rangwala H, Fatima H, Mubarak F Cureus. 2024; 16(1):e51863.

PMID: 38327950 PMC: 10848880. DOI: 10.7759/cureus.51863.

References

Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daude H . Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol. 2016; 131(3):525-546. DOI: 10.1007/s11060-016-2318-3. View

Shen S, Chen L, Liu J, Yang L, Zhang M, Wang L . Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma. Cancer Biol Med. 2020; 17(3):555-568. PMC: 7476097. DOI: 10.20892/j.issn.2095-3941.2020.0027. View

Kalbasi A, Ribas A . Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2019; 20(1):25-39. PMC: 8499690. DOI: 10.1038/s41577-019-0218-4. View

Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X . Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. J Immunother. 2016; 39(4):171-80. DOI: 10.1097/CJI.0000000000000122. View

Brat D, Aldape K, Colman H, Holland E, Louis D, Jenkins R . cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol. 2018; 136(5):805-810. PMC: 6204285. DOI: 10.1007/s00401-018-1913-0. View

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

Zhang N, Wei L, Ye M, Kang C, You H . Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma. Front Immunol. 2020; 11:592612. PMC: 7734213. DOI: 10.3389/fimmu.2020.592612. View

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

10.

Wei S, Duffy C, Allison J . Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018; 8(9):1069-1086. DOI: 10.1158/2159-8290.CD-18-0367. View

11.

Berghoff A, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A . Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2014; 17(8):1064-75. PMC: 4490866. DOI: 10.1093/neuonc/nou307. View

12.

Carpentier A, Ferrari D, Bailon O, Ursu R, Banissi C, Dubessy A . Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients. Eur J Neurol. 2012; 19(10):1337-42. DOI: 10.1111/j.1468-1331.2012.03766.x. View

13.

Ostrom Q, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C . CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015; 17 Suppl 4:iv1-iv62. PMC: 4623240. DOI: 10.1093/neuonc/nov189. View

14.

Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J . Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res. 2019; 38(1):87. PMC: 6380009. DOI: 10.1186/s13046-019-1085-3. View

15.

Datta M, Chatterjee S, Perez E, Gritsch S, Roberge S, Duquette M . Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models. Proc Natl Acad Sci U S A. 2023; 120(6):e2219199120. PMC: 9963691. DOI: 10.1073/pnas.2219199120. View

16.

Nayak L, Molinaro A, Peters K, Clarke J, Jordan J, de Groot J . Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020; 27(4):1048-1057. PMC: 8284901. DOI: 10.1158/1078-0432.CCR-20-2500. View